Taro Announces Completion of $250 Million Share Repurchase Program

HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it recently completed its $250 million share repurchase program. The company bought back 1,801,099 of its ordinary shares in open market transactions at an average price of $138.80 per share. The repurchase program was announced by the company on March 15, 2016, and was completed on August 18, 2016.

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160819005714/en/

Taro Pharmaceutical Industries Ltd.
William J. Coote, 914-345-9001
[email protected]

Source: Taro Pharmaceutical Industries Ltd.

You May Also Be Interested In

• Remittix Confirms Major Exchange Launch Price At $0.35 Minimum For RTX
• JASIWAY Best-Selling Modern Sleeper Sofa Chair Launches on Wayfair, Bringing Flexible Small-Space Living to Modern American Homes
• XRP Price Prediction: XRP Eyes $2 Breakout, But AlphaPepe Targets Returns That XRP Can’t Match